Literature DB >> 29439087

High Constitutive Activity Accounts for the Combination of Enhanced Direct Activation and Reduced Potentiation in Mutated GABAA Receptors.

Allison L Germann1, Daniel J Shin1, Christina R Kuhrau1, Alexander D Johnson1, Alex S Evers1, Gustav Akk2.   

Abstract

GABAA receptors activated by the transmitter GABA are potentiated by several allosterically acting drugs, including the intravenous anesthetic propofol. Propofol can also directly activate the receptor, albeit at higher concentrations. Previous functional studies have identified amino acid residues whose substitution reduces potentiation of GABA-activated receptors by propofol while enhancing the ability of propofol to directly activate the receptor. One interpretation of such observations is that the mutation has specific effects on the sites or processes involved in potentiation or activation. We show here that divergent effects on potentiation and direct activation can be mediated by increased constitutive open probability in the mutant receptor without any specific effect on the interactions between the allosteric drug and the receptor. By simulating GABAA receptor activity using the concerted transition model, we demonstrate that the predicted degree of potentiation is reduced as the level of constitutive activity increases. The model further predicts that a potentiating effect of an allosteric modulator is a computable value that depends on the level of constitutive activity, the amplitude of the response to the agonist, and the amplitude of the direct activating response to the modulator. Specific predictions were confirmed by electrophysiological data from the binary α1β3 and concatemeric ternary β2α1γ2L+β2α1 GABAA receptors. The corollaries of reduced potentiation due to increased constitutive activity are isobolograms that conform to simple additivity and a loss of separation between the concentration-response relationships for direct activation and potentiation.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29439087      PMCID: PMC5878668          DOI: 10.1124/mol.117.111435

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  30 in total

1.  The problem of synergism and antagonism of combined drugs.

Authors:  S LOEWE
Journal:  Arzneimittelforschung       Date:  1953-06

2.  Occupation of either site for the neurosteroid allopregnanolone potentiates the opening of the GABAA receptor induced from either transmitter binding site.

Authors:  John Bracamontes; Megan McCollum; Caroline Esch; Ping Li; Jason Ann; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2011-04-15       Impact factor: 4.436

3.  On the application of "a plausible model" of allosteric proteins to the receptor for acetylcholine.

Authors:  A Karlin
Journal:  J Theor Biol       Date:  1967-08       Impact factor: 2.691

4.  Tryptophan mutations at azi-etomidate photo-incorporation sites on alpha1 or beta2 subunits enhance GABAA receptor gating and reduce etomidate modulation.

Authors:  Deirdre Stewart; Rooma Desai; Qi Cheng; Aiping Liu; Stuart A Forman
Journal:  Mol Pharmacol       Date:  2008-09-19       Impact factor: 4.436

5.  The actions of propofol on inhibitory amino acid receptors of bovine adrenomedullary chromaffin cells and rodent central neurones.

Authors:  T G Hales; J J Lambert
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

6.  GABA Type A Receptor Activation in the Allosteric Coagonist Model Framework: Relationship between EC50 and Basal Activity.

Authors:  Gustav Akk; Daniel J Shin; Allison L Germann; Joe Henry Steinbach
Journal:  Mol Pharmacol       Date:  2017-11-17       Impact factor: 4.436

Review 7.  Monod-Wyman-Changeux allosteric mechanisms of action and the pharmacology of etomidate.

Authors:  Stuart A Forman
Journal:  Curr Opin Anaesthesiol       Date:  2012-08       Impact factor: 2.706

8.  Steroid interaction with a single potentiating site is sufficient to modulate GABA-A receptor function.

Authors:  John R Bracamontes; Joe Henry Steinbach
Journal:  Mol Pharmacol       Date:  2009-01-28       Impact factor: 4.436

9.  A propofol binding site on mammalian GABAA receptors identified by photolabeling.

Authors:  Grace M S Yip; Zi-Wei Chen; Christopher J Edge; Edward H Smith; Robert Dickinson; Erhard Hohenester; R Reid Townsend; Karoline Fuchs; Werner Sieghart; Alex S Evers; Nicholas P Franks
Journal:  Nat Chem Biol       Date:  2013-09-22       Impact factor: 15.040

10.  Correction for Inhibition Leads to an Allosteric Co-Agonist Model for Pentobarbital Modulation and Activation of α1β3γ2L GABAA Receptors.

Authors:  Alexis M Ziemba; Stuart A Forman
Journal:  PLoS One       Date:  2016-04-25       Impact factor: 3.240

View more
  5 in total

Review 1.  Applying the Monod-Wyman-Changeux Allosteric Activation Model to Pseudo-Steady-State Responses from GABAA Receptors.

Authors:  Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2018-10-17       Impact factor: 4.436

2.  Monod-Wyman-Changeux Allosteric Shift Analysis in Mutant α1β3γ2L GABAA Receptors Indicates Selectivity and Crosstalk among Intersubunit Transmembrane Anesthetic Sites.

Authors:  Andrea Szabo; Anahita Nourmahnad; Elizabeth Halpin; Stuart A Forman
Journal:  Mol Pharmacol       Date:  2019-01-29       Impact factor: 4.436

Review 3.  Application of the Co-Agonist Concerted Transition Model to Analysis of GABAA Receptor Properties.

Authors:  Allison L Germann; Joe Henry Steinbach; Gustav Akk
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

Review 4.  Isobologram Analysis: A Comprehensive Review of Methodology and Current Research.

Authors:  Ruo-Yue Huang; Linlin Pei; QuanJin Liu; Shiqi Chen; Haibo Dou; Gang Shu; Zhi-Xiang Yuan; Juchun Lin; Guangneng Peng; Wei Zhang; Hualin Fu
Journal:  Front Pharmacol       Date:  2019-10-29       Impact factor: 5.810

5.  Activation of the Rat α1β2ε GABAA Receptor by Orthosteric and Allosteric Agonists.

Authors:  Allison L Germann; Ariel B Burbridge; Spencer R Pierce; Gustav Akk
Journal:  Biomolecules       Date:  2022-06-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.